$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

$pbyi Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000143774922025787 Filed on November 03, 2022

Income Statement

Concept	2022 Q4	2022 Q3
Revenue	$65.68M	$57.10M
YoY Change	18.64%	23.48%
Cost Of Revenue	$16.84M	$12.50M
YoY Change	41.54%	21.56%
Gross Profit	$48.84M	$44.61M
YoY Change	12.37%	24.03%
Gross Profit Margin	74.36%	78.12%
Selling, General & Admin	$25.04M	$23.96M
YoY Change	11.47%	-8.14%
% of Gross Profit	51.27%	53.72%
Research & Development	$13.78M	$11.25M
YoY Change	-2.71%	-40.26%
% of Gross Profit	28.22%	25.23%
Depreciation & Amortization	$2.207M	$200.0K
YoY Change	-2.82%	0.0%
% of Gross Profit	4.52%	0.45%
Operating Expenses	$38.82M	$35.21M
YoY Change	5.99%	-21.61%
Operating Profit	$10.02M	$2.393M
YoY Change	46.6%	-126.73%
Interest Expense	-$2.760M	$2.947M
YoY Change	2.03%	-5.58%
% of Operating Profit	-27.56%	123.15%
Other Income/Expense, Net	-$204.0K	-$2.686M
YoY Change	-271.43%	-92.47%
Pretax Income	-$5.312M	-$293.0K
YoY Change	-219.75%	-99.34%
Income Tax	$294.0K	$67.00K
% Of Pretax Income
Net Earnings	-$5.606M	-$360.0K
YoY Change	-232.72%	-99.19%
Net Earnings / Revenue	-8.54%	-0.63%
Basic Earnings Per Share		-$0.01
Diluted Earnings Per Share	-$0.12	-$0.01
COMMON SHARES
Basic Shares Outstanding	45.64M	45.56M
Diluted Shares Outstanding		45.57M

Balance Sheet

Concept	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$81.07M	$77.96M
YoY Change	-1.26%	-10.95%
Cash & Equivalents	$76.20M	$77.96M
Short-Term Investments	$4.873M	$0.00
Other Short-Term Assets	$2.429M	$4.110M
YoY Change	443.4%	811.31%
Inventory	$4.526M	$5.452M
Prepaid Expenses	$5.902M	$6.801M
Receivables	$40.35M	$28.03M
Other Receivables	$12.75M	$3.525M
Total Short-Term Assets	$134.3M	$122.4M
YoY Change	-4.1%	-10.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.146M	$1.282M
YoY Change	-34.74%	-33.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.660M	$2.968M
YoY Change	-0.11%	-36.45%
Total Long-Term Assets	$87.78M	$76.42M
YoY Change	1.4%	-14.49%
TOTAL ASSETS
Total Short-Term Assets	$134.3M	$122.4M
Total Long-Term Assets	$87.78M	$76.42M
Total Assets	$222.1M	$198.8M
YoY Change	-2.0%	-12.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.440M	$14.93M
YoY Change	-42.37%	-25.54%
Accrued Expenses	$53.03M	$39.69M
YoY Change	-42.71%	-56.28%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00
YoY Change
Total Short-Term Liabilities	$77.48M	$59.99M
YoY Change	-29.29%	-48.4%
LONG-TERM LIABILITIES
Long-Term Debt	$98.31M	$97.99M
YoY Change	1.25%	1.23%
Other Long-Term Liabilities	$24.66M	$18.63M
YoY Change	10.32%	-22.83%
Total Long-Term Liabilities	$98.31M	$97.99M
YoY Change	1.25%	1.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$77.48M	$59.99M
Total Long-Term Liabilities	$98.31M	$97.99M
Total Liabilities	$200.5M	$176.6M
YoY Change	-12.48%	-25.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.367B	-$1.361B
YoY Change	0.0%	-0.72%
Common Stock	$1.388B	$1.383B
YoY Change	1.76%	1.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.61M	$22.16M
YoY Change
Total Liabilities & Shareholders Equity	$222.1M	$198.8M
YoY Change	-2.0%	-12.16%

Cashflow Statement

Concept	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	-$5.606M	-$360.0K
YoY Change	-232.72%	-99.19%
Depreciation, Depletion And Amortization	$2.207M	$200.0K
YoY Change	-2.82%	0.0%
Cash From Operating Activities	$7.683M	$17.26M
YoY Change	-241.36%	64.4%
INVESTING ACTIVITIES
Capital Expenditures	$7.000M
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$4.873M	$7.998M
YoY Change	-205.45%	-278.93%
Cash From Investing Activities	-$11.87M	$7.998M
YoY Change	-356.94%	-278.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.431M	-53.00K
YoY Change	-121650.0%	-99.83%
NET CHANGE
Cash From Operating Activities	7.683M	17.26M
Cash From Investing Activities	-11.87M	7.998M
Cash From Financing Activities	2.431M	-53.00K
Net Change In Cash	-1.759M	25.20M
YoY Change	115.56%	-197.31%
FREE CASH FLOW
Cash From Operating Activities	$7.683M	$17.26M
Capital Expenditures	$7.000M
Free Cash Flow	$683.0K
YoY Change	-112.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-360000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-44672000	usd
	us-gaap	Net Income Loss NetIncomeLoss	5608000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-33350000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45567739
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40813609
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44290432
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-360000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44673000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40520041
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45567739
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5610000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33352000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	19738000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2830000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-53000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-360000	usd
	dei	Amendment Flag AmendmentFlag	false
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	22155000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	29469000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4282000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-44672000	usd
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45608814
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45608814
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41175507
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41175507
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	100000	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	200000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	8000000.0	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	8000000.0	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	8000000.0	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	8000000.0	usd
CY2022Q3	pbyi	Finitelived Intangible Asset Expected Amortization Year Six FinitelivedIntangibleAssetExpectedAmortizationYearSix	8000000.0	usd
CY2022Q3	pbyi	Finitelived Intangible Asset Expected Amortization Year Seven FinitelivedIntangibleAssetExpectedAmortizationYearSeven	8000000.0	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	2000000.0	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35703
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0683487
	dei	Entity Address Address Line1 EntityAddressAddressLine1	10880 Wilshire Boulevard, Suite 2150
	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90024
	dei	City Area Code CityAreaCode	424
	dei	Local Phone Number LocalPhoneNumber	248-6500
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40813609
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44464682
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40520041
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	PBYI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45640135
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77960000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63131000	usd
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	18975000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28030000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	32526000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	5452000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	7109000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6801000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8984000	usd
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	8850000	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	4110000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	447000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	122353000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	140022000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12053000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14017000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1282000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1756000	usd
CY2022Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	60114000	usd
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	66125000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2591000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3311000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	377000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1354000	usd
CY2022Q3	us-gaap	Assets Assets	198770000	usd
CY2021Q4	us-gaap	Assets Assets	226585000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	14927000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11174000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39691000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	92575000	usd
CY2022Q3	pbyi	Post Marketing Commitment Liability Current PostMarketingCommitmentLiabilityCurrent	1381000	usd
CY2021Q4	pbyi	Post Marketing Commitment Liability Current PostMarketingCommitmentLiabilityCurrent	2263000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3988000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3574000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	59987000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	109586000	usd
CY2022Q3	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	37000	usd
CY2021Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	915000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12923000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15975000	usd
CY2022Q3	pbyi	Postmarketing Commitment Liability Noncurrent PostmarketingCommitmentLiabilityNoncurrent	5674000	usd
CY2021Q4	pbyi	Postmarketing Commitment Liability Noncurrent PostmarketingCommitmentLiabilityNoncurrent	5463000	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	97994000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	97092000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	176615000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	229031000	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1383299000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1364309000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1361149000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1366757000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	22155000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2446000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	198770000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	226585000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	57102000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46245000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	162356000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	197798000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12495000	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10279000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	38257000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	51806000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	23961000	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26084000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	64939000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	93832000	usd
CY2022Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11253000	usd
CY2021Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	18836000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	38456000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	57702000	usd
CY2022Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	7000000	usd
CY2021Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	7000000	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	54709000	usd
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	55199000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	148652000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	203340000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-10922000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	2393000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8954000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	13704000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5542000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2446000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9198000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	216000	usd
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	13000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	294000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	147000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	2947000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	3121000	usd
	us-gaap	Interest Expense InterestExpense	8313000	usd
	us-gaap	Interest Expense InterestExpense	10089000	usd
CY2022Q3	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	-19000	usd
CY2021Q3	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	-24498000	usd
	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	-92000	usd
	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	-9781000	usd
CY2022Q3	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	usd
CY2021Q3	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-8146000	usd
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	usd
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-8146000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	64000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	71000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	176000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	173000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2686000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-35681000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7935000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-27696000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-293000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-44635000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5769000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33238000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	67000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	37000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	161000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	112000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-360000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-44672000	usd
	us-gaap	Net Income Loss NetIncomeLoss	5608000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-33350000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9793000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2000	usd
	us-gaap	Net Income Loss NetIncomeLoss	5608000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	22155000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-5951000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28381000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-33350000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-10922000	usd
	us-gaap	Net Income Loss NetIncomeLoss	5608000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-33350000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6713000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	8327000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9198000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	28381000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1000000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8146000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4496000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2744000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1657000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3752000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-3160000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-2574000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	3663000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-3190000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3753000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7971000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-53762000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3713000	usd
	pbyi	Increase Decrease In Postmarketing Commitment Liability IncreaseDecreaseInPostmarketingCommitmentLiability	-671000	usd
	pbyi	Increase Decrease In Postmarketing Commitment Liability IncreaseDecreaseInPostmarketingCommitmentLiability	-859000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23510000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	26085000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	-0	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	38073000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	18977000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	22571000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18977000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15502000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10000000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	208000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	98500000	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	-0	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	100000000	usd
	pbyi	Payment For Debt Extinguishment Debt Prepayment Cost And Other Extinguishment Costs PaymentForDebtExtinguishmentDebtPrepaymentCostAndOtherExtinguishmentCosts	-0	usd
	pbyi	Payment For Debt Extinguishment Debt Prepayment Cost And Other Extinguishment Costs PaymentForDebtExtinguishmentDebtPrepaymentCostAndOtherExtinguishmentCosts	8519000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1910000	usd
	pbyi	Installment Payments To Acquire Intangible Assets InstallmentPaymentsToAcquireIntangibleAssets	-0	usd
	pbyi	Installment Payments To Acquire Intangible Assets InstallmentPaymentsToAcquireIntangibleAssets	20000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9792000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-31929000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5259000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21346000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	75292000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	97454000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	80551000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	76108000	usd
	pbyi	Increase Decrease In Accounts Payable Acquired For Inprocess Research And Development IncreaseDecreaseInAccountsPayableAcquiredForInprocessResearchAndDevelopment	7000000	usd
	pbyi	Increase Decrease In Accounts Payable Acquired For Inprocess Research And Development IncreaseDecreaseInAccountsPayableAcquiredForInprocessResearchAndDevelopment	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	7412000	usd
	us-gaap	Interest Paid Net InterestPaidNet	7914000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	141000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	84000	usd
CY2022Q2	pbyi	Number Of Subsidiaries NumberOfSubsidiaries	1	pure
CY2021	pbyi	Number Of Subsidiaries NumberOfSubsidiaries	2	pure
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-400000	usd
	us-gaap	Net Income Loss NetIncomeLoss	5600000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23500000	usd
CY2022Q3	pbyi	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	78000000.0	usd
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40814000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44290000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b>Use of Estimates: </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The preparation of consolidated financial statements in conformity with Generally Accepted Accounting Principles ("GAAP") in the United States, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of revenues and expenses for the period presented. Accordingly, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">Significant estimates include estimates for variable consideration for which reserves were established. These estimates are included in the calculation of net revenues and include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7925589000
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8765991000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8688594000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8765991000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-360000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-44672000	usd
	us-gaap	Net Income Loss NetIncomeLoss	5608000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-33350000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45568000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40520000
CY2022Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2021Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	175000
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45568000
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40814000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44465000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40520000
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
CY2022Q3	pbyi	Sublease Agreement Potential Milestone Payments SubleaseAgreementPotentialMilestonePayments	579800000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	122000	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	2600000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	12200000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	495000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	510000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	525000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	134000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	1786000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	33997000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	46136000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	-0	usd
CY2022Q3	pbyi	Cash Cash Equivalents And Shortterm Investments Fair Value CashCashEquivalentsAndShorttermInvestmentsFairValue	46136000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	69849000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	usd
CY2021Q4	pbyi	Cash Cash Equivalents And Shortterm Investments Fair Value CashCashEquivalentsAndShorttermInvestmentsFairValue	69847000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b>Concentration of Risk: </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents, marketable securities, and accounts receivable, net. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at <em style="font: inherit;"> September 30, 2022</em> were approximat<span style="background-color:#ffffff;">ely </span>$80.5<span style="background-color:#ffffff;"> million. </span>The Company does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-<em style="font: inherit;">1/P</em>-<em style="font: inherit;">1</em> or better by Standard and Poor’s Rating Service and Moody’s Investors Service at the time of purchase.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company sells its products in the United States primarily through specialty pharmacies and specialty distributors. Therefore, wholesale distributors and large pharmacy chains account for a large portion of its accounts receivables, net and product revenues, net. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for doubtful accounts primarily based on the credit worthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company’s success depends on its ability to successfully commercialize NERLYNX. The Company currently has a single product and limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, NERLYNX, and expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company relies exclusively on <em style="font: inherit;">third</em> parties to formulate and manufacture NERLYNX and its drug candidates. The commercialization of NERLYNX and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those <em style="font: inherit;">third</em> parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company has <em style="font: inherit;">no</em> experience in drug formulation or manufacturing and does <em style="font: inherit;">not</em> intend to establish its own manufacturing facilities. The Company lacks the resources and expertise to formulate or manufacture NERLYNX and other drug candidates. While the drug candidates were being developed by Pfizer, both the drug substance and drug product were manufactured by <em style="font: inherit;">third</em>-party contractors. The Company is using the same <em style="font: inherit;">third</em>-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of NERLYNX. If the Company is unable to continue its relationships with <em style="font: inherit;">one</em> or more of these <em style="font: inherit;">third</em>-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on <em style="font: inherit;">one</em> or more <em style="font: inherit;">third</em>-party contractors to manufacture the commercial supply of drugs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q3	pbyi	Cash And Cash Equivalents And Restricted Cash In Excess Of Insured Limits CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits	80500000	usd
CY2022Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2025000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4569000	usd
CY2022Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2945000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1385000	usd
CY2022Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	482000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1155000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	5452000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	7109000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	45329000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	22674000	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	102000000	usd
CY2022Q3	pbyi	Average Incremental Borrowing Rate AverageIncrementalBorrowingRate	0.109	pure
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000000.0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6000000.0	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2000000.0	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	8000000.0	usd
CY2022Q3	pbyi	Finitelived Intangible Asset Expected Amortization Year Eight FinitelivedIntangibleAssetExpectedAmortizationYearEight	2000000.0	usd
CY2022Q3	pbyi	Trade Accounts Receivable Net Excluding License Revenue Receivable TradeAccountsReceivableNetExcludingLicenseRevenueReceivable	24505000	usd
CY2021Q4	pbyi	Trade Accounts Receivable Net Excluding License Revenue Receivable TradeAccountsReceivableNetExcludingLicenseRevenueReceivable	29646000	usd
CY2022Q3	pbyi	Royalty Revenue Receivable RoyaltyRevenueReceivable	3525000	usd
CY2021Q4	pbyi	Royalty Revenue Receivable RoyaltyRevenueReceivable	2880000	usd
CY2022Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	28030000	usd
CY2021Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	32526000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.72
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	547880
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	6.51
CY2022Q3	pbyi	Prepaid Cro Services Current PrepaidCROServicesCurrent	271000	usd
CY2021Q4	pbyi	Prepaid Cro Services Current PrepaidCROServicesCurrent	340000	usd
CY2022Q3	pbyi	Prepaid Other Clinical Development Current PrepaidOtherClinicalDevelopmentCurrent	2503000	usd
CY2021Q4	pbyi	Prepaid Other Clinical Development Current PrepaidOtherClinicalDevelopmentCurrent	2933000	usd
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	589000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3178000	usd
CY2022Q3	pbyi	Prepaid Professional Fess Current PrepaidProfessionalFessCurrent	877000	usd
CY2021Q4	pbyi	Prepaid Professional Fess Current PrepaidProfessionalFessCurrent	398000	usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2561000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2135000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6801000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8984000	usd
CY2022Q3	pbyi	Prepaid Cro Services Noncurrent PrepaidCROServicesNoncurrent	160000	usd
CY2021Q4	pbyi	Prepaid Cro Services Noncurrent PrepaidCROServicesNoncurrent	166000	usd
CY2022Q3	pbyi	Prepaid Other Clinical Development Expense Noncurrent PrepaidOtherClinicalDevelopmentExpenseNoncurrent	0	usd
CY2021Q4	pbyi	Prepaid Other Clinical Development Expense Noncurrent PrepaidOtherClinicalDevelopmentExpenseNoncurrent	577000	usd
CY2022Q3	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	217000	usd
CY2021Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	611000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	377000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1354000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	7178000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	10338000	usd
CY2021Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	90000000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	29886000	usd
CY2022Q3	pbyi	Other Current Assets Cares Act Credit Receivable OtherCurrentAssetsCaresActCreditReceivable	3848000	usd
CY2021Q4	pbyi	Other Current Assets Cares Act Credit Receivable OtherCurrentAssetsCaresActCreditReceivable	0	usd
CY2022Q3	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	262000	usd
CY2021Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	447000	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	4110000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	447000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	3700000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	3800000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	4384000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.109	pure
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1377000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5631000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5805000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5983000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1508000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	20304000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3393000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	16911000	usd
CY2022Q3	us-gaap	Sublease Income SubleaseIncome	100000	usd
	us-gaap	Sublease Income SubleaseIncome	300000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23875000	usd
CY2022Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	60114000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8572000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8617000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7290000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6861000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1282000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1756000	usd
CY2022Q3	us-gaap	Depreciation Depreciation	200000	usd
	us-gaap	Depreciation Depreciation	500000	usd
CY2022Q3	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	90000000	usd
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	66125000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000000.0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6000000.0	usd
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P7Y6M
CY2022Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	102000000	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4006000	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	97994000	usd
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	869770
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.50
CY2022Q3	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	2930000	usd
CY2021Q4	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	57137000	usd
CY2022Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	9067000	usd
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	8829000	usd
CY2022Q3	pbyi	Accrued Development Costs AccruedDevelopmentCosts	1843000	usd
CY2021Q4	pbyi	Accrued Development Costs AccruedDevelopmentCosts	2663000	usd
CY2022Q3	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	12376000	usd
CY2021Q4	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	11406000	usd
CY2022Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	4843000	usd
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	5083000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4179000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3878000	usd
CY2022Q3	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	916000	usd
CY2021Q4	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	911000	usd
CY2022Q3	pbyi	Accrued Professional Fees Liability Current AccruedProfessionalFeesLiabilityCurrent	679000	usd
CY2021Q4	pbyi	Accrued Professional Fees Liability Current AccruedProfessionalFeesLiabilityCurrent	672000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2346000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	674000	usd
CY2022Q3	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	326000	usd
CY2021Q4	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	690000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	186000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	632000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39691000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	92575000	usd
CY2022Q3	pbyi	Accrued Clinical Research Organization Services Noncurrent AccruedClinicalResearchOrganizationServicesNoncurrent	0	usd
CY2021Q4	pbyi	Accrued Clinical Research Organization Services Noncurrent AccruedClinicalResearchOrganizationServicesNoncurrent	878000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	37000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	37000	usd
CY2022Q3	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	37000	usd
CY2021Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	915000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	39728000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	93490000	usd
CY2021Q4	pbyi	Restructuring Percentage Of Reduction In Headcount RestructuringPercentageOfReductionInHeadcount	0.13	pure
CY2022Q3	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	1404000	usd
CY2021Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	502000	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4006000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4908000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	600000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1500000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2011Q4	pbyi	Ordinary Shares Ownership Percentage OrdinarySharesOwnershipPercentage	0.20	pure
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2830000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4282000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9198000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28381000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.72
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.90
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	835297
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	7.76
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	582353
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1200000	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1300000	usd

Files In Submission

Name	View Source	Status
0001437749-22-025787-index-headers.html	Edgar Link	pending
0001437749-22-025787-index.html	Edgar Link	pending
0001437749-22-025787.txt	Edgar Link	pending
0001437749-22-025787-xbrl.zip	Edgar Link	pending
ex_417270.htm	Edgar Link	pending
ex_417271.htm	Edgar Link	pending
ex_417272.htm	Edgar Link	pending
ex_417273.htm	Edgar Link	pending
ex_440480.htm	Edgar Link	pending
ex_440535.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbyi-20220930.xsd	Edgar Link	pending
pbyi20220930_10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
pbyi-20220930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
pbyi-20220930_def.xml	Edgar Link	unprocessable
pbyi-20220930_pre.xml	Edgar Link	unprocessable
pbyi20220930_10q_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
pbyi-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2022 Q4 Form 10-Q Financial Statement

#000143774922025787 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2022 Q4 Form 10-Q Financial Statement

#000143774922025787 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi